• AAPL 167.04
  • TSLA 149.9
  • AMZN 179.17
  • MSFT 404.33
  • INTC 35.04
  • EURUSD 1.0656
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. SA /
  3. ABBV34.SA

AbbVie Inc. (ABBV34 SA) stock market data APIs

R$53.62 -0.53(-1%) as of April 18, 2024

AbbVie Inc. Financial Data Overview

54.15
53.62
-
54.68
53.62
38.6342-57.4188
1 538 050 M
59.5055
28 330 M
54 318 M
0.0271
0.564
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ABBV34',
Type: 'Common Stock',
Name: 'AbbVie Inc.',
Exchange: 'SA',
CurrencyCode: 'BRL',
CurrencyName: 'Brazilian real',
CurrencySymbol: 'R$',
CountryName: 'Brazil',
CountryISO: 'BR',
OpenFigi: NULL,
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
}

AbbVie Inc. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 54 318 M
  • EBITDA 26 358 M
  • Earnings Per Share 0.91
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get AbbVie Inc. Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get AbbVie Inc. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get AbbVie Inc. latest news via APIs

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from...

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

−     Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper re...
Do you have any questions?
support@eodhistoricaldata.com